These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 3377457)
1. Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807). Jones RN; Barry AL Antimicrob Agents Chemother; 1988 Apr; 32(4):443-9. PubMed ID: 3377457 [TBL] [Abstract][Full Text] [Related]
2. Antimicrobial activity of U-76,252 (CS-807), a new orally administered cephalosporin ester, including recommendations for MIC quality control. Jones RN; Barry AL; Pfaller M; Allen SD; Ayers LW; Fuchs PC Diagn Microbiol Infect Dis; 1988 Jan; 9(1):59-63. PubMed ID: 3370932 [TBL] [Abstract][Full Text] [Related]
3. In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746. Chin NX; Neu HC Antimicrob Agents Chemother; 1988 May; 32(5):671-7. PubMed ID: 3260766 [TBL] [Abstract][Full Text] [Related]
4. Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity. Knothe H; Shah PM; Eckardt O Infection; 1991; 19(5):370-6. PubMed ID: 1800379 [TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporin. Jones RN; Barry AL Antimicrob Agents Chemother; 1988 Oct; 32(10):1576-82. PubMed ID: 3190185 [TBL] [Abstract][Full Text] [Related]
6. In vitro activity of RU29246. The metabolite of a new HR916 cephalosporin ester. Jones RN; Erwin ME; Barrett MS; Briggs BM; Johnson DM Diagn Microbiol Infect Dis; 1991; 14(6):473-83. PubMed ID: 1802534 [TBL] [Abstract][Full Text] [Related]
7. Cefditoren in vitro activity and spectrum: a review of international studies using reference methods. Jones RN; Pfaller MA; Jacobs MR; Appelbaum PC; Fuchs PC Diagn Microbiol Infect Dis; 2001; 41(1-2):1-14. PubMed ID: 11687308 [TBL] [Abstract][Full Text] [Related]
8. RU 29 246, the active compound of the cephalosporin-prodrug-ester HR 916. I. Antibacterial activity in vitro. Bauernfeind A; Jungwirth R; Eberlein E; Klesel N; Adam F; Isert D; Limbert M; Markus A; Schrinner E; Seibert G J Antibiot (Tokyo); 1992 Apr; 45(4):505-20. PubMed ID: 1592683 [TBL] [Abstract][Full Text] [Related]
9. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents. Peric M; Browne FA; Jacobs MR; Appelbaum PC Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118 [TBL] [Abstract][Full Text] [Related]
10. In vitro activity of Ro 19-5247 (T-2525) and interpretive criteria for disk diffusion susceptibility testing. Beskid G; Fallat V; Siebelist J; Durkin JW; Lipschitz ER; McGarry DH J Clin Microbiol; 1987 Jul; 25(7):1186-90. PubMed ID: 3112176 [TBL] [Abstract][Full Text] [Related]
11. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830). Jones RN; Barry AL Diagn Microbiol Infect Dis; 1989; 12(6):495-510. PubMed ID: 2560422 [TBL] [Abstract][Full Text] [Related]
12. BMY-28100, a new oral cephalosporin: antimicrobial activity against nearly 7,000 recent clinical isolates, comparative potency with other oral agents, and activity against beta-lactamase producing isolates. Jones RN; Barry AL Diagn Microbiol Infect Dis; 1988 Jan; 9(1):11-26. PubMed ID: 3259489 [TBL] [Abstract][Full Text] [Related]
13. In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin. Briggs BM; Jones RN; Erwin ME; Barrett MS; Johnson DM Diagn Microbiol Infect Dis; 1991; 14(5):425-34. PubMed ID: 1797457 [TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin compared with other parenteral cephems. Jones RN; Erwin ME; Barrett MS; Johnson DM; Briggs BM Diagn Microbiol Infect Dis; 1991; 14(4):301-9. PubMed ID: 1889181 [TBL] [Abstract][Full Text] [Related]
15. Antimicrobial activity and disk diffusion susceptibility testing of Ro 40-6890, the active metabolite of the new cephalosporin ester, Ro 41-3399. Pfaller MA; Barry AL; Fuchs PC Antimicrob Agents Chemother; 1993 Apr; 37(4):893-5. PubMed ID: 8494387 [TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activity of the two new oral cephalosporin metabolites RO 19-5247 and RO 15-8074. Aldridge KE; Schiro DD; Sanders CV Eur J Clin Microbiol; 1987 Oct; 6(5):564-9. PubMed ID: 3436316 [TBL] [Abstract][Full Text] [Related]
17. In vitro activity of cefpodoxime compared with other oral cephalosporins tested against 5556 recent clinical isolates from five medical centers. Sader HS; Jones RN; Washington JA; Murray PR; Gerlach EH; Allen SD; Erwin ME Diagn Microbiol Infect Dis; 1993; 17(2):143-50. PubMed ID: 8243035 [TBL] [Abstract][Full Text] [Related]
18. In vitro evaluation of cefixime (FK027, FR17027, CL284635): spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteria. Fuchs PC; Jones RN; Barry AL; Thornsberry C; Ayers LW; Gavan TL; Gerlach EH Diagn Microbiol Infect Dis; 1986 Jul; 5(2):151-62. PubMed ID: 3522088 [TBL] [Abstract][Full Text] [Related]
19. Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing. Ayers LW; Jones RN; Barry AL; Thornsberry C; Fuchs PC; Gavan TL; Gerlach EH; Sommers HM Antimicrob Agents Chemother; 1982 Nov; 22(5):859-77. PubMed ID: 6983862 [TBL] [Abstract][Full Text] [Related]
20. Antibacterial activity of the investigational oral and parenteral cephalosporin BK-218. Johnson DM; Jones RN Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):181-8. PubMed ID: 1396735 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]